Credit Suisse’s NanoViricides NNVC Stock Holding History

Credit Suisse’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-977	Closed	-$43K	–	4299
2016 Q1	$43K	Buy	+977	New	+$37.9K	﹤0.01%	3899

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Credit Suisse's NNVC Position: Q2 2016 in Review

Credit Suisse sold out of NanoViricides (NNVC) in Q2 2016, closing a stake of 977 shares — an estimated $43K sold.

Credit Suisse first reported a position in NNVC in Q1 2016 and held it in 1 quarter. The position peaked at $43K in Q1 2016. 51 funds tracked by Wall St. Rank hold NNVC as of Q2 2016.

Credit Suisse reported no remaining NanoViricides position as of Q2 2016 after selling out during the quarter.
Credit Suisse sold 977 NanoViricides shares in Q2 2016, an estimated $43K.
Credit Suisse first reported a position in NanoViricides in Q1 2016 and held it in 1 quarter.
Credit Suisse's NanoViricides position peaked at $43K in Q1 2016.
51 funds tracked by Wall St. Rank held NanoViricides as of Q2 2016.

Based on Credit Suisse's 13F filing for Q2 2016, filed 11 Aug 2016.